美国食品药品监督管理局（FDA）已正式接受Viatris公司提交的关于速效美洛昔康的新药申请。该药物旨在用于治疗中重度急性疼痛。这一进展标志着Viatris在疼痛管理治疗领域迈出了关键一步。
美国食品药品监督管理局（FDA）已正式接受Viatris公司提交的关于速效美洛昔康的新药申请。该药物旨在用于治疗中重度急性疼痛。这一进展标志着Viatris在疼痛管理治疗领域迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.